Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives.

As a pioneer in antibody-drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics since 1998. ADC technology is the foundation of three of our approved medicines: ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), and TIVDAK® (tisotumab vedotin-tftv). ADCETRIS has received approval in more than 75 countries around the world and continues to make a difference in the lives of patients with several types of CD30-expressing lymphomas. PADCEV, first approved by the FDA in late 2019, is used in the treatment of patients with certain types of metastatic urothelial (bladder) cancer. PADCEV marketing applications are under review in the European Union and in several other countries. TIVDAK received accelerated approval by the US FDA in September 2021, and is used for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

TUKYSA® (tucatinib), a small molecule tyrosine kinase inhibitor, was approved in the U.S. in 2020 for certain types of metastatic HER2-positive breast cancer. TUKYSA also has marketing authorization in Canada, Switzerland, the European Union, United Kingdom and several other countries.

To maximize the potential of our four approved medicines, we are conducting broad development programs designed to fully assess these therapies for patients in need.

Seagen is advancing a clinical development portfolio of several other novel therapies for solid tumors and blood-related cancers, including ADCs as well as novel immuno-oncology agents and empowered antibodies. Our vision is to improve the lives of people with cancer through innovative targeted therapies.

QUICK FACTS

Year Initiated Operations: 1998

Publicly Traded: Nasdaq: SGEN

Employees: ~2,800 worldwide

Passion: Helping people with cancer

Leaders in Technology: Antibody-drug conjugates (ADCs)

Locations: Headquartered in Seattle, Washington area; California, Switzerland, and Europe

Today, our research efforts are dedicated to advancing a pipeline of:

- Programs using our proprietary ADC technologies
- New classes of ADCs, novel empowered antibodies and other targeted cancer therapies
- ADCs in combination with checkpoint inhibitors

Our pipeline is designed with patients in mind, focusing on therapies that have the potential to address unmet medical needs.

To learn more about us, please visit seagen.com Twitter @SeagenGlobal

CLINICAL DEVELOPMENT PIPELINE

Seagen®

Program	Tumor Type	Phase 1	Phase 2	Phase 3
ADCETRIS® brentuximab vedotin	Diffuse large B-cell lymphoma			*
	Hodgkin lymphoma (HL)			
	HL or PTCL (unfit for combination chemotherapy)		*	
	HL and PTCL		*	
	HL (pediatrics)			
	PTCL (<10% CD30 expression)		*	
	Metastatic solid tumors			
PADCEV® enfortumab vedotin-ejfv	Cisplatin eligible muscle invasive bladder cancer			*
	Cisplatin ineligible muscle invasive bladder cancer			*
	Untreated locally advanced or metastatic urothelial cancer			*
	Locally advanced or metastatic malignant solid tumors			
	Urothelial Cancer		*, **	
	Non-muscle invasive bladder cancer			
TUKYSA® tucatinib	HER2+ metastatic breast cancer, multiple trials			*
	High-risk adjuvant HER2+ breast cancer			*
	HER2+ metastatic gastroesophageal cancer		*	
	HER2+ metastatic breast cancer			
	Metastatic solid tumors HER2 alterations			
	HER2+ metastatic colorectal cancer		*	
	HER2+ metastatic gastrointestinal cancer			
TIVDAK® tisotumab vedotin-tftv	Recurrent or metastatic cervical cancer			*
	Recurrent or metastatic cervical cancer			
	Advanced solid tumors			
	Platinum-resistant ovarian cancer			
Ladiratuzumab vedotin	Metastatic triple-negative breast cancer			
	Locally advanced or metastatic solid tumors			
	Metastatic breast cancer			
Disitamab vedotin	HER2 expressing urothelial cancer		*	
SEA-CD40	Melanoma and NSCLC			
	Solid tumors			
SEA-TGT	Advanced solid tumors and lymphomas			
SEA-BCMA	Relapsed/refractory multiple myeloma			
SEA-CD70	Myelodysplastic syndrome and acute myeloid leukemia			
SGN-CD228A	Solid tumors			
SGN-B6A	Solid tumors			
SGN-STNV	Solid tumors			
SGN-B7H4V	Solid tumors			
SGN-PDL1V	Solid tumors			
SGN-ALPV	Solid tumors			

* Registrational intent ** Phase 1b/2 The safety and efficacy of the above investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.